This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ARSD / Arylsulfatase D · IHC design guide
Design Immunohistochemistry for ARSD
Plan chromogenic ARSD staining in paraffin sections with the catalog antibody at 1:100–1:300 (datasheet). Compare the granular cytoplasmic pattern with high staining in bronchial respiratory epithelial cells and undetected staining in adipocytes (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ARSD Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Granular cytoplasm (HPA tissue IHC); lysosome (UniProt) | |
| Staining pattern | Granular cytoplasmic staining in multiple cell types (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Adipose tissue+2 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific) | |
| Caveat | Some cell types are unstained despite broad tissue staining (HPA tissue IHC) | |
| Regulation | Expression regulation not established (UniProt) | |
| Isoform / epitope | 3 isoforms; epitope impact unknown (UniProt) |
Section 1
Recommended ARSD IHC & IF Protocols
The catalog antibody’s IHC-P protocol appears alongside three published ARSD tissue IHC methods (PMC8560752; PMC10521731; PMC13547030).
| Sample | Paraffin-embedded human lung carcinoma tissue; fixative not specified (datasheet A08673-1) |
| Fixation | Image fixative and duration unreported (datasheet A08673-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-ARSD, 1:100-1:300 (datasheet A08673-1) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ARSD-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: General cytoplasmic expression with a granular pattern. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 retrieval at 95–98 °C for 20 min (page antigen retrieval rule).
Section 2
What Is the Expected ARSD Staining Pattern?
ARSD is annotated in lysosomes and has no transmembrane segment (UniProt P51689). In paraffin IHC, expect a granular cytoplasmic pattern (HPA: tissue IHC), including high staining in bronchial respiratory epithelial cells and appendix glandular cells (HPA: High). HPA rates its tissue staining Approved, with medium consistency between antibody staining and RNA expression (HPA: tissue IHC reliability). Interpret intensity within the identified cell population rather than across the whole section.
| Distinct cytoplasmic granules in bronchial respiratory epithelium or appendix glands, with readily visible signal. | This fits the reported granular cytoplasmic profile and High staining in those cell populations (HPA: tissue IHC). Score the relevant cells and compartment; neighboring unstained structures do not negate a positive result (general IHC practice). |
| Predominantly nuclear or sharply membranous staining, with little granular cytoplasmic signal. | That distribution conflicts with the lysosomal annotation (UniProt P51689) and the tissue IHC pattern (HPA: granular cytoplasm). Treat it as suspect; compare antibody and detection controls before assigning ARSD expression (general IHC practice). |
| Strong staining in adipocytes, ovarian stromal cells, or soft-tissue fibroblasts. | HPA reports ARSD as Not detected in these specific cell populations (HPA: tissue IHC). Unexpected staining may reflect cross-reactivity or endogenous detection activity; verify the cell identity and include appropriate reagent controls (general IHC practice). |
| Broad, uniform color across cells, extracellular spaces, or the entire section. | Uniform haze obscures the reported granular cytoplasmic profile (HPA: tissue IHC). Check background with a no-primary control, then review blocking, washes, and chromogen development (general IHC practice); haze alone does not establish ARSD staining. |
| No detectable signal in bronchial respiratory epithelial cells on an otherwise interpretable section. | Those cells are reported High by HPA (HPA: bronchus tissue IHC), so a blank result calls for a run check. Confirm tissue identity, positive-control performance, antibody dilution, retrieval, and detection steps (general IHC practice) before calling the sample negative. |
💡Expected ARSD appearanceCall a result positive when the relevant epithelial or glandular cells show clear granular cytoplasmic staining, potentially High in bronchus or appendix (HPA: tissue IHC); isolated nuclear, membranous, or uniform section-wide color is suspect against that profile (HPA: tissue IHC; general IHC practice).
| Tissue and cell selection | HPA reports High signal in adrenal, appendix, breast, and cervical glandular cells; bronchial respiratory epithelial cells; caudate neurons; cerebellar granular-layer cells; and cortical glia (HPA: tissue IHC). Match the score to the named cell type. |
| Validation strength | HPA004694 has IHC Approved status, and the tissue profile has medium consistency with RNA expression (HPA: antibody validation; HPA: tissue IHC). This supports pattern comparison but does not make every positive deposit target-specific. |
| Cellular compartment and processing | UniProt annotates a lysosomal location, a signal peptide at residues 1–33, a mature chain at 34–593, and no transmembrane segment (UniProt P51689). These annotations support intracellular interpretation; they do not locate this antibody's epitope. |
| IF/ICC: should its signal look identical? | HPA reports approved vesicle and lipid-droplet localization in ICC-IF, using an antibody with ICC Approved status (HPA: subcellular; HPA063835 validation). Use that as application-specific context; it does not redefine the granular cytoplasmic tissue IHC pattern (HPA: tissue IHC). |
| Isoforms and retrieval | UniProt lists three isoforms (UniProt P51689). Their tissue staining and the antibody's isoform coverage are unspecified here. No target-specific fixation sensitivity or retrieval condition is supplied; assess retrieval with controls as general IHC practice. |
| Situation | Likely cause | Next action |
|---|---|---|
| Positive tissue is blank. | A missed IHC step or unsuitable run conditions are possible (general IHC practice); bronchial respiratory epithelium is reported High (HPA: tissue IHC). | Check the positive-control slide and tissue identity, then review retrieval, antibody dilution, incubation, detection, and counterstain in the run record (general IHC practice). |
| Signal is faint but confined to cytoplasmic granules. | The location agrees with HPA's profile, while intensity can be hard to judge without a same-run reference (HPA: tissue IHC; general IHC practice). | Compare the same cell type in a reported High tissue and a no-primary control; score only granules distinguishable from background (HPA: tissue IHC; general IHC practice). |
| Every compartment has diffuse color. | Nonspecific reagent background or excess chromogen development may obscure the reported granular pattern (general IHC practice; HPA: tissue IHC). | Inspect a no-primary control and review blocking, wash steps, antibody dilution, and development time before interpreting the slide (general IHC practice). |
| An HPA Not detected cell population stains strongly. | Cross-reactivity or endogenous detection activity is possible; HPA reports adipocytes, ovarian stromal cells, and soft-tissue fibroblasts as Not detected (HPA: tissue IHC). | Confirm cell identity and use no-primary and detection-system controls; resolve background before treating the result as biological expression (general IHC practice). |
| Staining is mainly nuclear or membranous. | The distribution conflicts with lysosomal localization and granular cytoplasmic tissue staining (UniProt P51689; HPA: tissue IHC). | Review morphology and reagent controls, then compare with a reported High cell population in the same run (HPA: tissue IHC; general IHC practice). |
| IHC and ICC-IF images appear to emphasize different structures. | HPA describes granular cytoplasm in tissue IHC and vesicles plus lipid droplets in ICC-IF (HPA: tissue IHC; HPA: subcellular). The approved antibodies differ by application (HPA: antibody validation). | Interpret each image against its own application-specific reference and controls; do not use the ICC-IF localization alone to reject a tissue IHC result (HPA: tissue IHC; HPA: subcellular; general IHC practice). |
Experiment evidence
IHC & IF images showing ARSD staining
A08673-1 · IHCImmunohistochemistry analysis of paraffin-embedded human lung carcinoma tissue, using ARSD Antibody. The picture on the right is blocked wit
A08673-1 · IFImmunofluorescence analysis of MCF7 cells, using ARSD Antibody. The picture on the right is blocked with the synthesized peptide.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000006756-ARSD/tissue/cerebral+cortex#imid_20281305
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000006756-ARSD/tissue/colon#imid_20289647
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000006756-ARSD/tissue/liver#imid_20289656
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000006756-ARSD/tissue/kidney#imid_20289649
HPA · ICC-IF A-549Human Protein Atlas immunofluorescence, A-549, antibody HPA063835; green = ARSD, blue = nucleus, red = microtubules.
HPA · ICC-IF A-549Human Protein Atlas immunofluorescence, A-549, antibody HPA063835; green = ARSD, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ARSD IHC & IF
🧪Run adrenal gland first: its glandular cells should stain (HPA: High in adrenal gland glandular cells). Use adipose tissue as a negative tissue; adipocytes should remain unstained (HPA: Not detected in adipocytes). On the adrenal slide, assess neighboring nonglandular cells for background staining, without treating them as an HPA-verified negative population.
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ARSD in A-549, MCF-7, U2OS, with annotated localisation: Vesicles (approved), Lipid droplets (approved) (HPA subcellular).
Technical controls: Include no-primary (secondary-only) and host-species- and clonality-matched isotype controls, plus a peptide-block control; peptide blocking was used in the selected tissue-IHC example (caption: A08673-1). For chromogenic detection in adrenal gland, quench endogenous peroxidase and check controls for pigment that could be mistaken for staining (standard IHC practice).
⚠️Feasibility: A target-specific fixation window and retrieval requirement are unreported in the supplied evidence; the selected paraffin-section caption does not state a fixative (caption: A08673-1). The evidence does not establish whether frozen sections or IF would be easier, although ICC-IF images are available in A-549, MCF-7 and U2OS cells (HPA: subcellular). In adrenal tissue, distinguish chromogen signal from endogenous pigment using the control slides (standard IHC practice).
HPA tissue IHC evidence for ARSD
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Caudate | Neuronal cells | High | Protein (IHC) | HPA → |
Section 3
Advanced ARSD IHC Tips
Troubleshoot ARSD staining in paraffin sections by checking retrieval, cytoplasmic pattern, controls, and cell-specific scoring before interpreting signal.
Which retrieval conditions should I try first for weak ARSD staining?
Start with citrate buffer at pH 6.0, heated to 95–98 °C for 20 minutes (page retrieval setting). Let sections cool in retrieval buffer before washing, and keep heating and cooling consistent across the comparison set (standard IHC practice). If staining remains weak, compare a longer citrate retrieval with an otherwise identical section, watching for tissue damage and increased background (standard IHC practice). Score whether the change improves granular cytoplasmic staining, the reported tissue pattern, rather than simply increasing diffuse color (HPA: general cytoplasmic expression with a granular pattern). Keep the same antibody dilution and detection conditions during that comparison so retrieval is the variable being tested (standard IHC practice).
Could fixation explain weak or uneven ARSD staining in paraffin sections?
ARSD-specific fixation sensitivity is unknown because the selected tissue caption reports paraffin embedding but does not state a fixative (A08673-1 caption: fixative not stated). Record the fixative and fixation interval for each specimen, then compare sections processed under the same conditions before changing antibody or retrieval settings (standard IHC practice). For routinely formalin-fixed material, begin with citrate pH 6.0 retrieval at 95–98 °C for 20 minutes (page retrieval setting). If staining varies across a block, inspect morphology and section edges for processing differences while keeping detection exposure constant (standard IHC practice). A difference between fixation groups warrants a controlled comparison; it does not establish an ARSD-specific fixation effect (standard IHC practice).
Where should convincing ARSD staining appear within positive cells?
Look for cytoplasmic staining with a granular pattern in tissue sections (HPA: tissue IHC profile). Lysosomal localisation supports a punctate intracellular interpretation, while the protein has no annotated transmembrane segment (UniProt P51689: lysosome; topology). HPA also reports vesicles and lipid droplets in cell imaging, so compare any apparent compartment assignment with morphology and an appropriate compartment marker (HPA: approved subcellular locations; standard IHC practice). Diffuse nuclear staining alone is discordant with these reported locations and should prompt review of background, counterstain, and detection controls (HPA: tissue and subcellular profiles; standard IHC practice). Judge localisation within identifiable cells rather than from isolated brown deposits or damaged tissue (standard IHC practice).
How can epitope choice affect interpretation across ARSD isoforms?
ARSD has 3 annotated isoforms, so confirm which sequence the antibody epitope covers before treating staining as a measure of every isoform (UniProt P51689: alternative splicing). The precursor has a signal peptide at residues 1–33 and a mature chain at 34–593; an epitope in the signal peptide needs separate validation for tissue staining (UniProt P51689: processing). Annotated glycosylation sites occur at residues 61, 128, and 347, and Cys 89 is modified to 3-oxoalanine (UniProt P51689: PTMs). These annotations identify features to check against the mapped epitope but do not establish an effect on this antibody (UniProt P51689: PTMs; standard assay interpretation). Without an epitope map, report the result as ARSD immunoreactivity, not isoform-specific abundance (standard IHC practice).
How should I check an ARSD result by multiplex immunofluorescence?
For a separate IF experiment, pair ARSD with a marker for the cell population being evaluated and a compartment marker when testing punctate localisation (HPA: cell-specific tissue staining and approved vesicle location; standard IF practice). Choose spectrally separated fluorophores and place a weaker expected signal in a channel with low measured tissue autofluorescence; include single-color controls (standard IF practice). Because ARSD is reported in lysosomes and has no annotated transmembrane segment, select permeabilisation for access to an intracellular epitope after checking the antibody's epitope information (UniProt P51689: localisation and topology; standard IF practice). Titrate permeabilisation on matched samples to preserve puncta while admitting the antibodies (standard IF practice). Do not treat an IF pattern as proof of the chromogenic section result without matching cell identity and controls (standard assay interpretation).
What controls help separate ARSD signal from nonspecific brown staining?
Run a no-primary control and inspect any residual chromogen before attributing brown deposits to ARSD (standard chromogenic IHC practice). Block endogenous peroxidase according to the detection workflow, and compare matched sections with the same antibody incubation, washes, and development time (standard chromogenic IHC practice). The selected paraffin-section image includes a synthesized-peptide blocking comparison, which offers a product-specific specificity check for that image (A08673-1 caption). Inspect pigment, damaged edges, and necrotic areas separately from intact cellular staining (standard IHC practice). Give greater weight to reproducible granular cytoplasmic staining in identifiable cells than to staining shared by the no-primary control (HPA: tissue IHC profile; standard IHC practice).
How should I score ARSD staining across tissues or experimental groups? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and tissue region before scoring, then apply the same threshold to every section (standard IHC practice). Record the percentage of positive cells and staining intensity, or calculate an H-score using intensity categories 0–3 and the percentage in each category (standard IHC practice). Normalize counts or positive area to the number of evaluable cells or viable tissue area in mm², and document excluded necrotic or folded regions (standard IHC practice). Keep granular cytoplasmic signal separate from diffuse background in the scoring rules (HPA: tissue IHC profile; standard IHC practice). Report cell type and region alongside the score because HPA describes cell-specific differences across tissues (HPA: tissue IHC observations).
What makes an apparent ARSD-positive result credible rather than artefactual?
A credible result shows reproducible granular cytoplasmic staining in intact, identifiable cells, consistent with the reported tissue pattern and lysosomal location (HPA: tissue IHC profile; UniProt P51689: lysosome). As a cell-type check, HPA reports high staining in bronchial respiratory epithelial cells and no detection in adipocytes, although those observations do not validate every specimen (HPA: bronchus and adipose tissue IHC). Reconsider isolated nuclear staining, section-edge signal, and deposits over necrosis before calling a cell positive (HPA: reported localisation; standard IHC practice). Compare suspect areas with a no-primary control to identify detection background, including residual endogenous enzyme activity (standard chromogenic IHC practice). The selected peptide-blocked image supports specificity in its pictured paraffin-embedded lung carcinoma section, but its caption does not report the fixative (A08673-1 caption).
Boster reagents
Best ARSD / Arylsulfatase D IHC Antibodies
The catalog antibody has IHC data from paraffin-embedded human lung carcinoma tissue and IF data from MCF7 cells (IHC and IF image captions); its listed reactivity is human (catalog).
Real IHC data
Anti-Arylsulfatase D ARSD Antibody
Cat # A08673-1
A08673-1 will render with an IHC image of paraffin-embedded human lung carcinoma tissue and a peptide-blocked comparison (IHC image caption). Its listed applications include IHC and IF, and its IF image shows MCF7 cells with a peptide-blocked comparison (catalog; IF image caption).
Which to pick: Choose A08673-1 for human tissue IHC: its IHC caption shows paraffin-embedded human lung carcinoma tissue; the fixative is unreported (IHC image caption). For cellular IF, choose A08673-1 based on its MCF7 IF image; separate ICC validation is unreported (IF image caption; catalog applications). No cross-species option is documented: A08673-1 lists human reactivity, has a rabbit host, and reports no clone (catalog).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P51689 (ARSD_HUMAN, Arylsulfatase D).
- Human Protein Atlas. ARSD tissue IHC expression (reliability: Approved).
- Human Protein Atlas. ARSD subcellular location (ICC-IF): Localized to vesicles and lipid droplets..
- Human Protein Atlas. ARSD antibody validation summary (2 antibodies).
- ARSD, a novel ERα downstream target gene, inhibits proliferation and migration of breast cancer cells via activating Hippo/YAP pathway. Cell death & disease 2021 — PMC8560752.
- Arylsulfatase D is a prognostic biomarker that promotes glioma cells progression through JAK2/STAT3 pathway and M2 macrophage infiltration. Frontiers in oncology 2023 — PMC10521731.
- Arylsulfatase D promotes malignant phenotypes in glioblastoma cells and is linked to altered Hippo pathway phosphorylation. Frontiers in oncology 2026 — PMC13547030.
- PubMed PMID:7720070 — UniProt-cited evidence.
- PubMed PMID:11177574 — UniProt-cited evidence.
- PubMed PMID:15772651 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ARSD (Arylsulfatase D). Expected localisation Granular cytoplasm (HPA tissue IHC); lysosome (UniProt). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A08673-1 at 1:100-1:300 (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human lung carcinoma tissue; fixative not specified (datasheet A08673-1); 2. Fixation: Image fixative and duration unreported (datasheet A08673-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-ARSD, 1:100-1:300 (datasheet A08673-1); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific); Caveat: Some cell types are unstained despite broad tissue staining (HPA tissue IHC); Isoform / epitope: 3 isoforms; epitope impact unknown (UniProt); Regulation: Expression regulation not established (UniProt). Evidence: UniProt P51689, HPA tissue IHC · Approved, HPA ICC-IF · vesicles and lipid droplets., Datasheet A08673-1, PMC8560752, PMC10521731. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ARSD/immunohistochemistry-ihc-guide.